Paris, 05 August, 2024 – EUROAPI posted today its 2024 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2024. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports.
This report includes notably the 2024 half-year management report, the consolidated financial statements on 30 June 2024, and the Statutory Auditors’ review report on the half-yearly financial information.
Financial Calendar (all dates to be confirmed)
- 11 February 2025: FY 2024 Results
- 21 May 2025: 2025 AGM
- 29 July 2025: H1 2025 results
About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.
Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.
| Media Relations contact: Laurence Bollack Tel.: +33 (0)6 81 86 80 19 mr@euroapi.com | Investor Relations contacts: Sophie Palliez-Capian Tel.: +33 (0)6 87 89 33 51 Sophie.palliez@euroapi.com Camille Ricotier Tel: +33 (0)6 43 29 93 79 Camille.ricotier@euroapi.com |
Attachment
